TELEGRAFT Telemonitoring of home dialysis utilizing a smart biomimetic arteriovenous graft
- Coordinator
- Syddansk Universitet, Denmark
- Runs
- 1 September 2022 to 28 February 2027
- Status
- Running
- EU funding
- €4.4m
- Total cost
- €5.3m
- Partners
- 13 organisations in 7 countries
- Type
- Innovation Action
- Grant agreement
- 101057673
What the project is doing
In the project's own words, from its summary on CORDIS.
Clinical need: 10% of the population worldwide is affected by chronic kidney disease (CKD) and millions die each year because they do not have access to treatment. Giving global shortage of kidney donors, the vast majority of patients rely on hemodialysis (HD). Over 2.6M people worldwide currently receive HD to stay alive, yet this number may only represent 10% of people needing treatment. Solution: Up to 70% of current arteriovenous grafts (AVG) fail in the first year after implantation.
This is primarily due to thrombosis, luminal scar formation, and infection. In our ground-breaking new AVG, biomimicking zwitterions prevent thrombosis, drug delivery prevents scar formation and infection, and an ECM coating ensures fast tissue integration allowing early HD.Smart: TELEGRAFT comprises two diagnostic tools to monitor and prevent device complication. Pressure transmitters are used to monitor blood flow and optical sensors to detect inflammation and infections.
The data is processed by AI machine learning models and displayed in an easy to understand dashboard for healthcare professionals. The data allows online telemonitoring and consultations by remote healthcare professionals. This makes home dialysis safe for patients, even in areas with poor infrastructure, where patients live far from HD clinics. Surgical implantation: The TELEGRAFT system will be demonstrated in an operational environment through a 2-stage randomized clinical trial enrolling 60 patients at 5 hospitals across Europe and through a home HD field study.
Resource constrained setting: (1) In low and middle income countries, TELEGRAFT will substitute complicated and expensive kidney transplantation and allow simpler and cheap implantation of AVG for HD. (2) TELEGRAFT is the only solution with diagnostic tools allowing real-time online detection and remote monitoring of complications and device failure. This allows transition from HD at the hospital to the resource constrained home setting.
Topics
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Syddansk Universitet | Odense M | Denmark | Coordinator |
| Klinikum Der Technischen Universität München (tum Klinikum) | Muenchen | Germany | Participant |
| Leibniz-Institut Fuer Photonische Technologien E.v. | Jena | Germany | Participant |
| Biomodics Aps | Kgs Lyngby | Denmark | Participant |
| Region Syddanmark | Vejle | Denmark | Participant |
| Asociacion Instituto De Investigacion Sanitaria Biobizkaia | Barakaldo Bizkaia | Spain | Third party |
| Servicio Vasco de Salud Osakidetza | Vitoria-Gasteiz | Spain | Participant |
| Vilniaus Universiteto Ligonine Santaros Klinikos | Vilnius | Lithuania | Participant |
| Bmd Software Lda | Aveiro | Portugal | Participant |
| Region Stockholm | Stockholm | Sweden | Participant |
| Verigraft AB | Goteborg | Sweden | Participant |
| Aston University | Birmingham | United Kingdom | Associatedpartner |
| The University of Birmingham | Birmingham | United Kingdom | Associatedpartner |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI